Current prospects for immunization against cytomegaloviral disease

Infectious Agents and Disease

Volumn 5, Issue 1, 1996, Pages 29-35

  Adler, Stuart P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus disease; vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HUMANS; IMMUNIZATION; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TRANSPLANTATION IMMUNOLOGY; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0029671385     PISSN: 10562044     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Adler SP. Cytomegalovirus and child day care: risk factors for maternal infection. Pediatr Infect Dis J 1991;10:590-4.
2. Adler SP. Molecular epidemiology of cytomegalovirus: a study of factors affecting transmission among children at three day-care centers. Pediatr Infect Dis J 1991;10:584-90.
3. Adler SP. Hospital transmission of cytomegalovirus. Infect Agents Dis 1992;1:43-9.
4. Adler SP, Chandrika T, Lawrence L, Baggett J. Cytomegalovirus infections in neonates acquired by blood transfusion. Pediatr Infect Dis J 1983;2:114-8.
5. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32.
6. Adler SP, Finney JW, Manganello AM. Prevention of child-to-mother transmission of cytomegalovirus (CMV) by changing behaviors: a randomized controlled trial [Abstract]. Pediatr Res 1995;37:168A.
7. Balfour HH Jr, Welo PK, Sachs GW. Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplant Proc 1985;17:81-3.
8. Britt WJ. Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 1984;135:369-78.
9. Britt WJ, Auger D. Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus. J Virol 1986;58:185-91.
10. Britt WJ, Vugler LG. Processing of the gp55-116 envelope glycoprotein complex of human cytomegalovirus. J Virol 1989;63:403-10.
11. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990;64:1079-85.
12. Chandler SH, Handsfield HH, McDougall JK. Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted diseases. J Infect Dis 1987;155:655-60.
13. Chou S. Cytomegalovirus infection and reinfection transmitted by heart transplantation. J Infect Dis 1987;155:1054-6.
14. Collier AC, Chandler SH, Handsfield HH, Corey L, McDougall JK. Identification of multiple strains of cytomegalovirus in homosexual men. J Infect Dis 1989;159:123-6.
15. Drew WL, Sweet ES, Miner RC, Mocarski ES, Multiple infections by cytomegalovirus in patients with acquired immunodeficiency syndrome. Documentation by Southern blot hybridization. J Infect Dis 1984;150:952-3.
16. Dworsky M, Yow M, Stagno S, et al. Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics 1983;72:295-9.
17. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engt J Med 1992;326:663-7.
18. Gilbert MJ, Riddell SR, Li CR, Greenberg PD. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 1993;67:3461-9.
19. Glenn J. Cytomegalovirus infections following renal transplantation. Rev Infect Dis 1981;3:1151-78.
20. Gönczöl E, Furlini G, Ianacone J, Plotkin SA. A rapid microneutralization assay for cytomegalovirus. J Virol Methods 1986;14:37-41.
21. Hutto C, Ricks R, Garvie M, et al. Epidemiology of cytomegalovirus infections in young children: day care vs. home care. Pediatr Infect Dis 1985;4:149-52.
22. Istas AS, Demmler GJ, Dobbins JG, Stewart JA, Adler SP, National Congenital Cytomegalovirus Disease Registry Collaborating Group. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995;20:665-70.
23. Kumar ML, Nankervis GA, Cooper AR, et al. Postnatally acquired cytomegalovirus infections in infants of CMV-excreting mothers. J Pediatr 1984;104:669-73.
24. Liu Y-N, Kari B, Grehrz RC. Human immune responses to major human cytomegalovirus glycoprotein complexes. J Virol 1988;62:1066-70.
25. Liu Y-NC, Klaus A, Kari B, Stinski MF, Eckhardt J, Gehrz RC. The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B- and T-cell immune responses in humans. J Virol 1991;65:1644-8.
26. Marshall GS, Ricciardi RP, Rando RF, et al. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J Infect Dis 1990;162:1177-81.
27. Marshall GS, Rabalais GP, Stout GG, Waldeyer SL. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 1992;165:381-4.
28. + virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103-10.
29. Metselaar HJ, Rothbarth PH, Brouwer RML, et al. Prevention of cytomegalovirus-related death by passive immunization: a double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation 1989;48:264-6.
30. Metselaar HJ, Balk AHMM, Mochtar B, Rothbarth PH, Weimar W. Cytomegalovirus seronegative heart transplant recipients: prophylactic use of anti-CMV immunoglobulin. Chest 1990;97:396-9.
31. Murph JR, Bale JF Jr. The natural history of acquired cyto-megalovirus infection among children in group day care. Am J Dis Child 1988;142:843-6.
32. Pass RF, August AM, Dworsky M, et al. Cytomegalovirus infection in a day-care center. TV Engl J Med 1982;307:477-79.
33. Pass RF, Hutto C, Ricks R, Cloud GA. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. N Engl J Med 1986;314:1414-6.
34. Pass RF, Duliege AM, Boppana SB, et al. Immunogenicity of a recombinant CMV gB vaccine. Pediatr Res 1995;37:185A.
35. Plotkin SA, Huang E-S. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 1985;152:395-7.
36. Plotkin SA, Farquhar J, Hornberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 1976;134:470-5.
37. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991;114:525-31.
38. Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994;58:1176-8.
39. Porath A, McNutt RA, Smiley LM, Weigle KA. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Rev Infect Dis 1990;12:31-40.
40. Quinnan GV Jr, Kirmani N, Esber E, et al. HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients. J Immunol 1981;126:2036-41.
41. Quinnan GV Jr, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bonemarrow-transplant recipients. N Engl J Med 1982;307:7-13.
42. Rasmussen LE, Nelson RM, Kelsall DC, Merigan TC. Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci USA 1984;81:876-80.
43. Rasmussen L, Matkin C, Spaete R, Pachl C, Merigan TC. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 1991;164:835-42.
44. + cytotoxic t lymphocyte responses to human cytomegalovirus in immunode-ficient humans by the adoptive transfer of T cell clones. In: Michelson S, Plotkin SA, eds. Multidisciplinary approach to understanding cytomegalovirus disease, Amsterdam: Excerpta Medica, 1993:155-64.
45. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivation of the inoculum. J Infect Dis 1995;171:1387-98.
46. Saliba G, Arulnaden JL, Gugenheim J, Serves C, et al. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc 1989;21:2260-2.
47. Snydman DR, McIver J, Leszczynksi J, et al. A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients. Transplantation 1984;38:553-7.
48. Snydman DR, Werner BG, Heinze-Lacy BH, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 1987;317:1049-54.
49. Spector SA, Hirata KK, Neuman TR. Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J Infect Dis 1984;150:953-6.
50. Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy, incidence, transmission to fetus, and clinical outcome. JAMA 1986;256:1904-8.
51. Steinmuller DR, Graneto D, Swift C, et al. Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus infection post living-related-donor renal transplantation. Transplant Proc 1989;21:2069-71.
52. Steinmuller DR, Novic AC, Streem SB, Graneto D, Swift C. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infections. Transplantation 1990;49:68-70.
53. Taber LH, Frank AL, Yow MD, et al. Acquisition of cytomegaloviral infections in families with young children: a serological study. J Infect Dis 1985;151:948-52.
54. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infection in newborn infants. J Pediatr 1981;98:281-7.
55. Zaia JA, Levin MJ, Preblud SR. The status of passive immunization for herpesvirus infections. In: Alving BM, Finlay son JS, eds. Immunoglobulins: characteristics and uses of intravenous preparations. U.S. Dept of Health and Human Services publication no. (FDA) 80-9005. 1979:111-21.